Amino Asylum
Amino Asylum scored 25/100 on Panya's 11-signal vendor rubric. Each signal is scored 0 to 100, the methodology is public, and our affiliate posture is flat-fee · never pay-to-rank. Below is the full per-signal breakdown.
- COA on every lothistoric COAs flagged by independent reviewers as missing verification codes and client fields typical of legitimate lab reports35
- Cold-chain verified30
- Rx legalityresearch-chemical sale model; FDA raided warehouse June 2025 and operations were halted0
- Compound identitylimited third-party testing; no comprehensive independent verification35
- Dose accuracy35
- Endotoxin testing25
- Refund posturepayment processing terminated, pending orders frozen post-raid0
- Channel claritysite offline; channel can no longer be assessed30
- Support qualityoperations halted; no functional support channel10
- Price transparencyhistoric per-mg pricing; site offline60
- Longitudinal retentionFDA enforcement action June 2025 ended operations15
Brand pharmacy supply stable. Compounded channel sunsetting · April 30, 2026 FDA proposal to exclude tirzepatide from the 503B bulks list (comment closes June 29, final rule likely Q3 2026) closes the mass-compounded path. 503A patient-specific compounding survives only with documented medical necessity. Telehealth platforms (Hims, Ro, Mochi) pivoting toward brand prescriptions or oral alternatives.
Recovered from the 2023 shortage. Diabetes-coded insurance straightforward.
Oral semaglutide. Niche fit for needle-averse patients. Lower bioavailability than injectable.
Recovered from the 2023-24 shortage. Insurance coverage expanding under 2025-26 employer plans. Oral Wegovy 25mg launched Jan 2026 at $149/mo · adds a needle-free path. Compounded semaglutide channel similarly narrowing under post-Feb-2025 enforcement-discretion rules.
Lilly-direct LillyDirect channel (US-only) supplements pharmacy distribution. Stable. Brand-channel demand expected to lift through 2026 as compounded pathway closes under the April 30 FDA 503B-exclusion proposal · LillyDirect's at-launch pricing materially undercuts compounded for patients without insurance coverage.
The 11-signal rubric is public.
Identity, dose accuracy, COA, cold-chain, Rx legality, compound identity, endotoxin testing, refund posture, channel clarity, support quality, price transparency, longitudinal retention. Each scored 0 to 100. Vendors that fail our floor are silently filtered out · they don't appear in our match flow at all.
If Amino Asylum wants to dispute or update this score, contact partner@panya.health. Score updates are recorded on this page with a public changelog.
People asking about Amino Asylum
Want a match for your situation?
Take the 2-minute quiz. We'll match you against this and the other vendors in your region · based on your dose, urgency, and budget.
We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.